| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 68,38 | 69,32 | 14:51 | |
| 67,46 | 69,14 | 14:41 |
| Stück | Geld | Kurs | Brief | Stück |
|---|---|---|---|---|
| 76,00 | 10 | |||
| 71,40 | 342 | |||
| 70,68 | 122 | |||
| 70,20 | 2.900 | |||
| 70,16 | 342 | |||
| 69,72 | 700 | |||
| 69,58 | 700 | |||
| 69,36 | 122 | |||
| 69,32 | 122 | |||
| 69,30 | 272 | |||
Quelle: [URL] https://aktienkurs-orderbuch.finanznachrichten.de/kk3a.htm [/URL] | ||||
| 122 | 68,36 | |||
| 122 | 68,34 | |||
| 300 | 68,32 | |||
| 122 | 68,30 | |||
| 700 | 68,14 | |||
| 700 | 67,90 | |||
| 2.900 | 67,68 | |||
| 162 | 67,54 | |||
| 162 | 66,32 | |||
| Summe Aktien im Kauf | Verhältnis | Summe Aktien im Verkauf | ||
| 5.290 | 1,065 | 5.632 | ||
| Uhrzeit | Aktienkurs | Stück |
|---|---|---|
| 29.07.2026 | 17:38:10 | 69,60 | 21 |
| Tagesumsatz Xetra | - | 0 |
Angaben in grüner Schrift zeigen, dass der Aktienkurs im Vergleich zum vorherigen Kurs gestiegen ist. Angaben in roter Schrift zeigen gefallene Börsenkurse.
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 13:58 | Cytokinetics' cardiomyopathy drug cleared for NHS use | 2 | pharmaphorum | ||
| 12:24 | Cytokinetics, Incorporated: Cytokinetics Announces MHRA Marketing Authorisation for MYQORZO (aficamten) and Positive Guidance from NICE for Symptomatic Obstructive Hypertrophic Cardiomyopathy in England and Wales | 97 | GlobeNewswire (Europe) | Authorisation from MRHA and Recommendation from NICE This announcement is intended for business and financial media and investors only SOUTH SAN FRANCISCO, Calif., July 30, 2026 (GLOBE NEWSWIRE) --... ► Artikel lesen | |
| 23.07. | Cytokinetics, Incorporated: Cytokinetics to Announce Second Quarter Results on August 6, 2026 | 1 | GlobeNewswire (USA) | ||
| CYTOKINETICS Aktie jetzt für 0€ handeln | |||||
| 17.07. | Cytokinetics, Incorporated: Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 2 | GlobeNewswire (USA) | ||
| 15.07. | Wall Street Analysts Think Cytokinetics (CYTK) Could Surge 30.54%: Read This Before Placing a Bet | 1 | Zacks |
| Zeit | Aktuelle Nachrichten | Medien | ||
|---|---|---|---|---|
| 11:12 | Biotech Stocks At 52-Week Highs - ANIK & CHE Rise With Q2 Results, ICUI, NBIX, RPRX | AFX News | LONDON (dpa-AFX) - The following biotech stocks reached a 52-week high on July 29, 2026, driven by key catalysts such as the release of second quarter financial results and ongoing clinical... ► Artikel lesen | |
| 12:42 | LEADS BIOLABS CO., LTD.: Leads Biolabs' Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Completes Patient Enrollment in Phase II Study for Biliary Tract Cancer, Further Demonstrating Breakthrough Potential in Immune-Cold Tumors | GlobeNewswire (Europe) | NANJING, China, July 30, 2026 (GLOBE NEWSWIRE) -- Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company," Stock Code: 9887.HK) announced that the Phase II clinical study of its core product... ► Artikel lesen | |
| 12:10 | BeOne Medicines: Vom Blockbuster zur Onkologie-Plattform | sharedeals.de | Der ehemals unter dem Namen BeiGene bekannte Biotechkonzern BeOne Medicines entwickelt sich zunehmend von einem Unternehmen mit einem einzelnen Wachstumstreiber zu einem breit aufgestellten Anbieter... ► Artikel lesen | |
| 13:06 | Bicycle Therapeutics plc: Bicycle Therapeutics Reports Recent Business Progress and Second Quarter 2026 Financial Results | Business Wire | Data presented at AACR and ASCO provide further validation of the potential of Bicycle technology to deliver oncology therapeutics with improved benefit/risk profiles compared to existing modalities... ► Artikel lesen | |
| 13:18 | Regeneron Pharmaceuticals Inc Bottom Line Retreats In Q2 | AFX News | WASHINGTON (dpa-AFX) - Regeneron Pharmaceuticals Inc (REGN) revealed a profit for second quarter that Drops, from the same period last yearThe company's earnings totaled $1.296 billion, or $12.23... ► Artikel lesen |